Search ↗

Comparison

Argireline vs Matrixyl

Both are cosmetic & topical, so the meaningful differences are in kinetics, evidence and regulatory status.

Argireline Matrixyl
Class Cosmetic & topical Cosmetic & topical
Evidence Clinical trials Clinical trials
Human trials ~8 ~10
Half-life Topical; not systemically absorbed in meaningful quantity Topical
Reported range 5-10 mg 3-8 mg
Frequency Applied topically 1-2x daily at 5-10% concentration Applied topically 1-2x daily at 3-8% concentration
Routes Topical Topical
FDA approved No No
Research use only No No
Banned in sport No No
Studied for Expression line reduction, Anti-ageing skincare Collagen stimulation, Wrinkle reduction, Skin firmness
Reported side effects Mild local irritation, Transient redness Mild local irritation

Argireline

Argireline is a synthetic peptide patterned on the N-terminal sequence of SNAP-25, a component of the SNARE complex that mediates vesicle fusion during neurotransmitter release. By competing with native SNAP-25 for a position in the complex it modestly reduces acetylcholine release at the neuromuscular junction, softening expression-line formation. The comparison to botulinum toxin is a marketing frame rather than an equivalence: the effect is far weaker, and penetration through intact stratum corneum is the limiting factor.

Matrixyl

Matrixyl is the pentapeptide KTTKS, a subfragment of type I procollagen, conjugated to palmitic acid to allow it to cross the lipid barrier of the stratum corneum. The fragment acts as a feedback signal that collagen has been degraded, prompting fibroblasts to increase synthesis of collagen I, collagen III and fibronectin. Controlled split-face human studies have shown measurable improvement in wrinkle depth, which puts it ahead of most of the cosmetic peptide category on evidence. It is not the same as Matrixyl 3000, a different blend of palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7.

Argireline vs Matrixyl: common questions

What is the difference between Argireline and Matrixyl?

Both are cosmetic & topical. Argireline: A hexapeptide marketed as topical botulinum toxin, working on the same SNARE machinery by a much weaker mechanism. Matrixyl: A palmitoylated collagen fragment and one of the few cosmetic peptides with credible controlled human data.

Which has stronger evidence, Argireline or Matrixyl?

They sit at the same evidence level: clinical trials. Argireline has about 8 human studies and Matrixyl about 10.

Are Argireline and Matrixyl FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 71587772) ↗ · structure, identifiers, synonyms
  2. CAS Registry Number 616204-22-9 ↗ · chemical identity
  3. CAS Registry Number 214047-00-4 ↗ · chemical identity

Published literature

  1. Chan LKW, Lee KWA, Lee CH, et al.. Cosmeceuticals in photoaging: A review.Skin Res Technol 2024.PubMed 39233460 · doi:10.1111/srt.13730
  2. Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy.Int J Mol Sci 2025.PubMed 40565185 · doi:10.3390/ijms26125722
  3. Nagendran ST, Ali MJ, Dogru M, et al.. Complications and adverse effects of periocular aesthetic treatments.Surv Ophthalmol 2022.PubMed 33933438 · doi:10.1016/j.survophthal.2021.04.009
  4. Wisniewski JD, Ellis DL, Lupo MP. Facial rejuvenation: combining cosmeceuticals with cosmetic procedures.Cutis 2014.PubMed 25279473
  5. Bruschi M, Alberici F, Moroni G, et al.. The landscape of serum autoantibodies in lupus nephritis.Autoimmun Rev 2026.PubMed 42409299 · doi:10.1016/j.autrev.2026.104128
  6. Wang Y, Wang M, Xiao S, et al.. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.Am J Clin Dermatol 2013.PubMed 23417317 · doi:10.1007/s40257-013-0009-9
  7. Bongard O, Weimer D, Lemoine R, et al.. Cyclosporine toxicity in renal transplant recipients detected by nailfold capillaroscopy with Na-fluorescein.Kidney Int 2000.PubMed 11115091 · doi:10.1046/j.1523-1755.2000.00441.x
  8. Young B, Zhao X, Cook AR, et al.. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis.Vaccine 2017.PubMed 27939013 · doi:10.1016/j.vaccine.2016.11.013
  9. Röper B, Kaisig D, Auer F, et al.. Thêta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care?.Strahlenther Onkol 2004.PubMed 15127162 · doi:10.1007/s00066-004-1174-9
  10. Kaczvinsky JR, Griffiths CE, Schnicker MS, et al.. Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging.J Cosmet Dermatol 2009.PubMed 19735523 · doi:10.1111/j.1473-2165.2009.00444.x
  11. Osborne R, Hakozaki T, Laughlin T, et al.. Application of genomics to breakthroughs in the cosmetic treatment of skin ageing and discoloration.Br J Dermatol 2012.PubMed 22670614 · doi:10.1111/j.1365-2133.2012.10960.x

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.